IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines

IO Biotech has raised €127 million ($155 million) to fund clinical development of immune-modulating IDO and PD-L1 cancer vaccines. The series B financing round comes months after IO Biotech showed combining its IDO and PD-L1 vaccines with Opdivo triggered complete responses in 45% of stage 4 melanoma patients.